Penny Stock

IMCI came to my attention recently and after doing my research, seeing IMCI just broke a major resistance level I knew I’d have to share it with my readers!

Remember VMware’s IPO. They are a major software maker for the virtualization industry. VMW quickly went from around $55 to over $122 a share!!!

A current theme I notice companies doing is to use software technology to help minimize hardware purchasing and maintenance which

consolidates their servers. Instead of having a separate file and mail server. Here’s where IMCI really shines.

IMCI can setup the solutions to put both on 1 computer.

Virtualization saves a company money…huge money if it’s implemented on an enterprise business level which I think IMCI has the potential to do.

Notice the .50 cent resistance point for the last 2 months

The short term shows that it has broken resistance at .50 cents.

IMCI could go much higher!!

To learn more about IMCI visit their website at: http://www.igius.com

I believe IMCI deserves to be considered for your watchlist.

Do your own research on IMCI before it possibly breaks out to much higher levels.

Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our sites, newsletters or emails unless you can afford to lose your entire investment. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.Com and Crown Equity Holdings, Inc., its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand dollars from a third party for 2 days of advertisement services for Infinite Group Inc. IMCI

Wednesyday September 30, 2009

******************************************************************

La Mesa, CA — September 30, 2009 — Axia Group, Inc. (Pink Sheets: AGIJ - News) announces today that it has entered into a Letter of Intent (LOI) with Yana Philanthropy Group, a Taiwanese company. Contingent upon the satisfaction of certain conditions including satisfactory due diligence, the parties anticipate closing of a definitive agreement in October which shall result in Yana becoming the controlling shareholder and majority owner of Axia.

Yana Philanthropy is the first venture philanthropy organization in Asia which promotes the value of corporate social responsibility by advocating spiritual growth and responsibility which it believes will lead to both a spiritual and wealthy love by awakening the human consciousness. Yana also provides a platform which unites professionals from different backgrounds can work together. Yana Philanthropy has been in business for nine years and has been focused on the education and development of individual spiritual level. Yana International Co. Ltd., a subsidiary of Yana , has formed a joint venture with Great Sun Hospital Management Corp. in Taiwan to own and operate medical clinics. As part of this joint venture, Yana Philanthropy has created Yana Clinics to assist the medical community with spiritual healing courses, teaching spiritual healing and training volunteers throughout the world. Yana Philanthropy also anticipates building a green energy society in Taiwan that will work to build green energy houses, schools and clinics, eventually expanding this business to an international level. Through these subsidiary businesses, Yana Philanthropy will generate the funds necessary to carry out its philanthropic mission.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Axia Group, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. Axia Group, Inc. cautions you that any forward-looking information provided by or on behalf of Axia Group, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Axia Group, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Axia Group, Inc.’s control. In addition to those discussed in Axia Group, Inc.’s press releases, public filings, and statements by Axia Group, Inc.’s management, including, but not limited to, Axia Group, Inc.’s estimate of the sufficiency of its existing capital resources, Axia Group, Inc.’s ability to raise additional capital to fund future operations, Axia Group, Inc.’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Axia Group, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Axia Group, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contact: David Keaveney at dk@zhongguopartners.com

dspa120002-090930

******************************************************************

***********Advertisement***********

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Stock Hot Tips publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold StockHotTips.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Rule 17B requires disclosure of payment for investor relations.

LOS ANGELES (CRWENewswire) Cavitation Technologies, Inc. (CTI) (OTC Bulletin Board: CVAT & Berlin: WTC) is pleased to announce Producer’s Choice Soy Energy (www.pcsoyenergy.com) Moberly, MO biodiesel production plant is performing above expectations.

According to Charles Mandeville, Chemist, SRS Engineering, Inc. “The CTI BioForce 9000 is doing its job very well, providing excellent conversion rates, exceeding all our expectations and performance requirements. The fuel quality is the best we have ever seen.”

Roman Gordon, CTI CEO, stated, “We knew that our unit would provide excellent performance and are very pleased by this news confirming our technology performs much better than others. We believe there is a bright future for BioForce 9000, which offers many advantages for new production plants, which gives them an edge over other producers. Feedstock flexibility, higher yields and top quality fuel will allow plants to be more profitable than existing producers. This will show existing plants that by replacing older outdated technologies, they can improve profitability as well.” Mr. Gordon went on further to say, “We have many clients who are now moving forward with their projects for new plants in South America, Asia and other parts of the world.”

CTI’s BioForce 9000 nano-cavitation biodiesel reactor is a unique low cost single stage reactor and is the most advanced system available today for quality biodiesel production. The BioForce 9000 offers substantial savings over existing technologies, which reduce equipment, and production costs substantially. Its ability to process multiple feedstocks and reduce energy costs is a significant advantage for producers.

The Producer’s Choice Soy Energy is the first of many companies, which are planning to utilize CTI’s BioForce 9000 and SRS systems technologies. The plant was designed and constructed by Process Concepts (www.processconcepts.com) and SRS Engineering, Inc. (www.srsengineering.com). CTI is also working with Desmet Ballestra, the world’s leading provider of biodiesel plants, to install the CTI BioForce 9000 in some of their plants.

About Cavitation Technologies

Cavitation Technologies, Inc. (CTI); (OTCBB: CVAT - News); is a “Green-Tech” company, established in 2006 to become a world leader in the development of new cutting edge technologies for the, vegetable oil refining, renewable fuel, petroleum, water treatment, wastewater sanitation, food and beverage, chemical industries. For additional information please visit: www.cavitationtechnologies.com

Safe Harbor: Pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995, and within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Exchange Act of 1934, any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals and assumptions of future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this release may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” or statements indicating certain actions such as “may,” “could,” or “might” occur. Such statements reflect the current views of CTI with respect to future events and are subject to certain assumptions, including those described in this release. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products, services, and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. Cavitation Technologies, Inc. does not undertake any responsibility to update the “forward-looking” statements contained in this news release.

For Further Information Contact:
Cavitation Technologies
(818) 718-0905
info@cavitationtechnologies.com
IR@cavitationtechnologies.com

*********************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) Crown Equity Holdings, Inc. (CRWE.OB) has received five thousand shares of free trading stock from a third party for advertising services for Cavitation Technologies, Inc. (CVAT.OB) and an additional twenty-five thousand shares of 144 restricted stock from Cavitation Technologies, Inc. (CVAT.OB) for 12 months of advertisement services.

North Palm Springs, CA - (CRWENewswire) - September 29, 2009 — Aquentium, Inc. (OTCBB: AQNM) a publicly traded company with a focus on “green technologies” is pleased to announce that the company’s non-chemical technology sanitizes fruits and vegetables naturally without the use of any chemicals.

The Aquentium non-chemical sanitation equipment is designed for improved food safety standards both domestically and internationally. Aquentium is currently offering exclusive representation opportunities for its complete line of non-chemical processing and sanitation equipment for fruits and vegetables in countries throughout the world as well in all fifty states in the USA

The goal at Aquentium is to help prevent contamination of fresh fruits and vegetables. The Aquentium non-chemical process can extend the shelf life of produce which means higher profits for food processors and less waste for the consumer.

The uniqueness of the Aquentium technology is that it is over 50% more effective than chemicals and over 3,000 times faster acting than chemicals. Ultimately, Aquentium believes that we have better technology to combat e-coli, salmonella, listeria and other bacteria or viruses than what most food processors are currently using.

With the Aquentium equipment, a processor does not have to stop processing to do plant sanitation. This increases plant production. Furthermore, food processors can expect an ROI in less than 12 months using the Aquentium equipment.

About Aquentium

Aquentium is a diversified company with an emphasis on green technologies. The company currently has interests in non-chemical sanitation equipment, waste-to-energy, water treatment, food safety, mining, alternative energy, building materials, affordable housing, re-deployable housing, and recycling.

www.aquentium.com

email: ir@aquentium.com

Note: Certain statements in this news release may contain “forward-looking” information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. There can be no assurance that such forward-looking statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.

Mark Taggatz
Aquentium
PO Box 580943
North Palm Springs, CA 92258
USA

Phone: 951-657-8832

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to holdCRWESelect.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is being paid 100,000 restricted shares for public relations services for Aquentium Inc. (AQNM)

PWRM - Stock on the Move !

PWRM - From $0.02 cents to $0.16 cents in past month… WHY ???

MEMBER ALERTS - Many of you writing in about PWRM and why is it on our front page and we don’t talk more about it… It is a compensated alert as one of our featured profiles and we just leave it to you to do your own research… It has been performing very well and it appears the news is just getting started… So, if you didn’t look at it first time around… check into it now…

PWRM - Has been one of our front page featured emerging growth companies for some time now… and the stock has climbed over the past several weeks from $0.02 to its current $0.15 and messageboards and stock blogs have been alight with chatter about the potential to be realized with Power 3 Medicals patent portfolio for the earliest detection methods of several high profile diseases….

PWRM hits gains of 55% Monday trading 14,414,292 by the close of the market Monday September 28, 2009 Power 3 Medical Products Inc.

Power3 Medical Products, Inc, operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets.

_______________________________________

Technical chart

Web Site: http://www.Power3Medical.com

“The Rationale for a Blood Test to Detect Early Breast Cancer.”

Power3 Medical Products, Inc. announced in May 2009 that results for the early stage diagnosis from clinical validation trials of the NuroPro? PD test for Parkinson’s disease are better than expected. The NuroPro PD test was developed to help clinicians distinguish patients with Parkinson’s disease from “normal” individuals and patients with other neurological disorders. The NuroPro PD test, developed by Power3, utilizes a panel of blood serum protein biomarkers evaluated by biostatistical analysis to predict the probability that a patient has Parkinson’s disease.

Power3 Medical Products, Inc. announced in May 2009 a significant breakthrough related to the diagnosis of patients with Alzheimer’s. This breakthrough, which involved the successful diagnoses of different forms of Alzheimer’s, including high-risk patients, was achieved during the initial phase of clinical validation trials of the Company’s NuroPro® AD blood test. Prospective clinical validation trials of the NuroPro® AD for newly drawn samples, phase one for which is now complete, confirmed previous results recorded by Power3. The NuroPro AD test was developed to help clinicians diagnose patients with Alzheimer’s, as well as to distinguish those with Alzheimer’s from normal individuals and patients with other neurological disorders.

“For physicians to order a test for a patient, they first need to believe in it. That takes major international scientific acceptance and publication in peer-reviewed journals. This meeting is an excellent opportunity to showcase worldwide the strides we have made through refinements in our biomarkers and blood test for early stage detection of breast cancer (BC-SeraPro, GLOBE NEWSWIRE Aug. 20, 2009),” said Dr. Goldknopf. “Earlier presentations on Alzheimer’s and Parkinson’s disease biomarkers and tests were given at the annual meetings of the American Academy of Neurology in Seattle and the International Congress of Alzheimer’s Disease in Vienna (NuroPro, World Stock Wire July 14, 2009). We recently published the Parkinson’s disease biomarkers and test results in Biochemical and Biophysical Research Communications (Reute rs Sept. 2, 2009), and more publications are in the works.”

Power3 Medical Products is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets.

Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer’s disease (NuroPro-AD) and Parkinson’s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, and breast cancer.

Take a Look at PWRM Website and Stay Tuned for More !!!

Web Site: http://www.Power3Medical.com

Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our sites, newsletters or emails unless you can afford to lose your entire investment. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com and Crown Equity Holdings, Inc., its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for the completion of building a website and advertising for Power 3 Medical Products Inc. (PWRM.OB)